MARK2 and breast cancer: Given that MAP3K1 is a serine/threonine kinase involved in multiple signaling pathways and that its loss-of-function mutations are known to drive tumorigenesis24, our findings suggest that kinase fusions may represent an alternative mechanism for kinase pathway activation in breast cancer, independent of mutational events.